Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has announcements × Urothelial Cancer × Docetaxel × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 3 Breast Neoplasms 3 Parkinson Disease 4, Autosomal Dominant Lewy Body 2 Esophageal Neoplasms 2 Urothelial Cancer 1 Urinary Bladder Neoplasms 1 Ureteral Neoplasms 1 Ovarian Neoplasms 1 Fallopian Tube Neoplasms 1 Carcinoma, Ovarian Epithelial 1

Interventions

pembrolizumab 2 erdafitinib 2 Gemcitabine 2 Cisplatin 2 Carboplatin 2 vinflunine 1 enfortumab vedotin 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Docetaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03390504 2026-02-02

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting

629 enrolled 32 charts 1 FDA

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡